CAR T-Cell therapy with concurrent ibrutinib for chronic lymphocytic leukaemia

Dr Jordan Gauthier gives a press conference at ASH 2018 about the comparison of efficacy and toxicity of CD19-specific chimeric antigen receptor T-Cells alone or in combination with ibrutinib for relapsed and/or refractory chronic lymphocytic leukaemia (CLL).

Watch his interview with ecancer here:

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php